Although the ICI antibody avelumab, targeting programmed death ligand 1 (PD-L1), has failed to improve OS or PFS in clinical trials treating newly diagnosed and recurrent glioblastoma patients when administered as monotherapy in addition to standard of care, two clinical trials are currently investigating avelumab vaccine combinations. This evidence concerns the gene CD274 and glioblastoma.